PRAC Inhibitors
The chemical class known as PRAC inhibitors comprises a diverse group of small-molecule compounds that can influence the activity of a protein referred to as PRAC. These inhibitors are not unified by a common chemical structure but rather by their ability to modulate signaling pathways and cellular processes that can affect the activity of PRAC. The modulatory effect can occur through several distinct mechanisms, including the inhibition of kinases, proteasomes, and other enzymes that control the cellular localization, turnover, or modification of proteins. This class includes compounds that can inhibit kinases involved in major signaling pathways like PI3K/AKT/mTOR and MAPK, which are pivotal in various aspects of cellular regulation. By altering the phosphorylation status of downstream targets, these inhibitors can adjust the activity of transcription factors and other proteins that regulate gene expression, thereby exerting an influence on PRAC.
Additionally, PRAC inhibitors can affect the ubiquitin-proteasome system, a critical pathway responsible for protein degradation. By blocking the function of the proteasome, these inhibitors can lead to the accumulation of proteins within the cell, which can influence the concentration and activity of PRAC. Furthermore, some members of this class can modulate epigenetic markers, such as DNA methylation and histone acetylation. By altering the epigenetic landscape, these compounds can change the expression patterns of genes, including those that encode for PRAC or its regulatory elements. This action can have a significant impact on the protein's function. The diversity of the mechanisms through which these inhibitors act reflects the complexity of the cellular processes they target and underscores the multifaceted approaches that can be employed to modulate the function of proteins such as PRAC. In summary, PRAC inhibitors represent a varied class of compounds that can influence the activity of PRAC by targeting different molecular pathways and processes within the cell.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which could inhibit PRAC by affecting multiple signaling pathways, including those that might involve nuclear protein regulation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MAP kinase kinase (MEK), which could inhibit PRAC by preventing the activation of the MAPK/ERK pathway, potentially influencing proteins regulated by this pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that could inhibit PRAC by leading to the accumulation of proteins, potentially affecting the turnover of proteins like PRAC and its regulatory factors. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that could inhibit PRAC by disrupting downstream signaling, including AKT activation, which might affect PRAC function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that could inhibit PRAC by affecting cell growth and metabolism signaling pathways, potentially impacting proteins associated with these processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that could inhibit PRAC by interfering with the degradation of proteins, which could result in altered levels of proteins such as PRAC. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which could inhibit PRAC by modulating the activity of transcription factors and affecting nuclear protein function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that could inhibit PRAC by altering chromatin structure and gene expression, potentially influencing nuclear proteins like PRAC. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
An MDM2 antagonist that could inhibit PRAC by activating p53 signaling, potentially affecting cell cycle and apoptosis pathways that might modulate PRAC. | ||||||